---
document_datetime: 2025-12-29 07:40:17
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/ryzneuta.html
document_name: ryzneuta.html
version: success
processing_time: 0.1068696
conversion_datetime: 2025-12-30 10:28:57.713197
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Ryzneuta

[RSS](/en/individual-human-medicine.xml/230709)

##### Authorised

This medicine is authorised for use in the European Union

efbemalenograstim alfa Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Ryzneuta](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Ryzneuta is a medicine that stimulates the production of white blood cells. It is used to reduce the duration of neutropenia (low levels of neutrophils, a type of white blood cell) and the occurrence of febrile neutropenia (neutropenia with fever) in patients receiving cytotoxic chemotherapy (medicines to treat cancer by killing cells).

Ryzneuta is not intended for use in patients with chronic myeloid leukaemia or myelodysplastic syndromes (conditions in which large numbers of abnormal blood cells are produced).

Ryzneuta contains the active substance efbemalenograstim alfa.

Expand section

Collapse section

## How is Ryzneuta used?

Ryzneuta can only be obtained with a prescription and treatment should be started and supervised by a doctor who has experience in the treatment of cancer or blood disorders. It is given as an injection under the skin at least 24 hours after the end of each cycle of chemotherapy.

For more information about using Ryzneuta, see the package leaflet or contact your doctor or pharmacist.

## How does Ryzneuta work?

Chemotherapy can cause neutropenia, which may increase the risk of infections. The active substance in Ryzneuta, efbemalenograstim alfa, is very similar to a protein called granulocyte colony-stimulating factor (G-CSF), which is involved in the production of white blood cells in the bone marrow. Ryzneuta works like G-CSF and helps the bone marrow make more white blood cells, thereby treating neutropenia.

## What benefits of Ryzneuta have been shown in studies?

The benefits of Ryzneuta were investigated in three main studies involving patients receiving myelotoxic chemotherapy (medicines to treat cancer that kill blood cells) to treat breast cancer. The studies measured the number of days in which patients had severe neutropenia after starting chemotherapy.

In a study involving 122 patients, those given Ryzneuta experienced an average of 2.9 fewer days of severe neutropenia compared with patients given placebo (a dummy treatment): 1.3 days and 3.9 days, respectively.

In a second study involving 393 patients, patients given Ryzneuta were compared with patients given pegfilgrastim (another medicine to treat neutropenia which, like Ryzneuta, is also given once per chemotherapy cycle): both groups experienced 0.2 days with severe neutropenia on average.

A third study was carried out in 242 women who needed chemotherapy after surgery for breast cancer. In this study, patients given Ryzneuta and patients given filgrastim (another medicine to treat neutropenia, which is given once a day) experienced 0.7 days of severe neutropenia on average.

## What are the risks associated with Ryzneuta?

For the full list of side effects and restrictions with Ryzneuta, see the package leaflet.

Side effects with Ryzneuta mostly concern pain in bone and muscles. The most common side effect (which may affect more than 1 in 10 people) is bone pain. Other side effects (which may affect up to 1 in 10 people) include pain in the back, joints and extremities (arms, hands, legs and feet).

## Why is Ryzneuta authorised in the EU?

In patients given chemotherapy to treat their cancer, Ryzneuta reduced the duration of severe neutropenia as much as pegfilgrastim and filgrastim (other available treatments) and no new safety concerns were identified compared to what is known of other G-CSF medicines used in clinical practice. The European Medicines Agency decided that Ryzneuta's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Ryzneuta?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Ryzneuta have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Ryzneuta are continuously monitored. Suspected side effects reported with Ryzneuta are carefully evaluated and any necessary action taken to protect patients.

## Other information about Ryzneuta

Ryzneuta received a marketing authorisation valid throughout the EU on 21 March 2024.

Ryzneuta : EPAR - Medicine overview

Reference Number: EMA/53795/2024

English (EN) (108.98 KB - PDF)

**First published:** 13/05/2024

[View](/en/documents/overview/ryzneuta-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-838)

български (BG) (132.84 KB - PDF)

**First published:**

13/05/2024

[View](/bg/documents/overview/ryzneuta-epar-medicine-overview_bg.pdf)

español (ES) (108.86 KB - PDF)

**First published:**

13/05/2024

[View](/es/documents/overview/ryzneuta-epar-medicine-overview_es.pdf)

čeština (CS) (130.55 KB - PDF)

**First published:**

13/05/2024

[View](/cs/documents/overview/ryzneuta-epar-medicine-overview_cs.pdf)

dansk (DA) (108.36 KB - PDF)

**First published:**

13/05/2024

[View](/da/documents/overview/ryzneuta-epar-medicine-overview_da.pdf)

Deutsch (DE) (112.16 KB - PDF)

**First published:**

13/05/2024

[View](/de/documents/overview/ryzneuta-epar-medicine-overview_de.pdf)

eesti keel (ET) (106.92 KB - PDF)

**First published:**

13/05/2024

[View](/et/documents/overview/ryzneuta-epar-medicine-overview_et.pdf)

ελληνικά (EL) (131.3 KB - PDF)

**First published:**

13/05/2024

[View](/el/documents/overview/ryzneuta-epar-medicine-overview_el.pdf)

français (FR) (109.98 KB - PDF)

**First published:**

13/05/2024

[View](/fr/documents/overview/ryzneuta-epar-medicine-overview_fr.pdf)

hrvatski (HR) (131.01 KB - PDF)

**First published:**

13/05/2024

[View](/hr/documents/overview/ryzneuta-epar-medicine-overview_hr.pdf)

italiano (IT) (107.46 KB - PDF)

**First published:**

13/05/2024

[View](/it/documents/overview/ryzneuta-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (139.21 KB - PDF)

**First published:**

13/05/2024

[View](/lv/documents/overview/ryzneuta-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (130.08 KB - PDF)

**First published:**

13/05/2024

[View](/lt/documents/overview/ryzneuta-epar-medicine-overview_lt.pdf)

magyar (HU) (128.6 KB - PDF)

**First published:**

13/05/2024

[View](/hu/documents/overview/ryzneuta-epar-medicine-overview_hu.pdf)

Malti (MT) (132.16 KB - PDF)

**First published:**

13/05/2024

[View](/mt/documents/overview/ryzneuta-epar-medicine-overview_mt.pdf)

Nederlands (NL) (109.22 KB - PDF)

**First published:**

13/05/2024

[View](/nl/documents/overview/ryzneuta-epar-medicine-overview_nl.pdf)

polski (PL) (132.57 KB - PDF)

**First published:**

13/05/2024

[View](/pl/documents/overview/ryzneuta-epar-medicine-overview_pl.pdf)

português (PT) (109.92 KB - PDF)

**First published:**

13/05/2024

[View](/pt/documents/overview/ryzneuta-epar-medicine-overview_pt.pdf)

română (RO) (128.59 KB - PDF)

**First published:**

13/05/2024

[View](/ro/documents/overview/ryzneuta-epar-medicine-overview_ro.pdf)

slovenčina (SK) (130.23 KB - PDF)

**First published:**

13/05/2024

[View](/sk/documents/overview/ryzneuta-epar-medicine-overview_sk.pdf)

slovenščina (SL) (129.22 KB - PDF)

**First published:**

13/05/2024

[View](/sl/documents/overview/ryzneuta-epar-medicine-overview_sl.pdf)

Suomi (FI) (106.62 KB - PDF)

**First published:**

13/05/2024

[View](/fi/documents/overview/ryzneuta-epar-medicine-overview_fi.pdf)

svenska (SV) (107.78 KB - PDF)

**First published:**

13/05/2024

[View](/sv/documents/overview/ryzneuta-epar-medicine-overview_sv.pdf)

Ryzneuta : EPAR - Risk management plan summary

English (EN) (493.94 KB - PDF)

**First published:** 13/05/2024

[View](/en/documents/rmp-summary/ryzneuta-epar-risk-management-plan-summary_en.pdf)

## Product information

Ryzneuta : EPAR - Product information

English (EN) (1.11 MB - PDF)

**First published:** 13/05/2024

**Last updated:** 03/09/2025

[View](/en/documents/product-information/ryzneuta-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-420)

български (BG) (1.05 MB - PDF)

**First published:**

13/05/2024

**Last updated:**

03/09/2025

[View](/bg/documents/product-information/ryzneuta-epar-product-information_bg.pdf)

español (ES) (1.01 MB - PDF)

**First published:**

13/05/2024

**Last updated:**

03/09/2025

[View](/es/documents/product-information/ryzneuta-epar-product-information_es.pdf)

čeština (CS) (1.08 MB - PDF)

**First published:**

13/05/2024

**Last updated:**

03/09/2025

[View](/cs/documents/product-information/ryzneuta-epar-product-information_cs.pdf)

dansk (DA) (1018.59 KB - PDF)

**First published:**

13/05/2024

**Last updated:**

03/09/2025

[View](/da/documents/product-information/ryzneuta-epar-product-information_da.pdf)

Deutsch (DE) (1.03 MB - PDF)

**First published:**

13/05/2024

**Last updated:**

03/09/2025

[View](/de/documents/product-information/ryzneuta-epar-product-information_de.pdf)

eesti keel (ET) (1.02 MB - PDF)

**First published:**

13/05/2024

**Last updated:**

03/09/2025

[View](/et/documents/product-information/ryzneuta-epar-product-information_et.pdf)

ελληνικά (EL) (901.91 KB - PDF)

**First published:**

13/05/2024

**Last updated:**

03/09/2025

[View](/el/documents/product-information/ryzneuta-epar-product-information_el.pdf)

français (FR) (1016.91 KB - PDF)

**First published:**

13/05/2024

**Last updated:**

03/09/2025

[View](/fr/documents/product-information/ryzneuta-epar-product-information_fr.pdf)

hrvatski (HR) (1.05 MB - PDF)

**First published:**

13/05/2024

**Last updated:**

03/09/2025

[View](/hr/documents/product-information/ryzneuta-epar-product-information_hr.pdf)

íslenska (IS) (1012.48 KB - PDF)

**First published:**

13/05/2024

**Last updated:**

03/09/2025

[View](/is/documents/product-information/ryzneuta-epar-product-information_is.pdf)

italiano (IT) (1.02 MB - PDF)

**First published:**

13/05/2024

**Last updated:**

03/09/2025

[View](/it/documents/product-information/ryzneuta-epar-product-information_it.pdf)

latviešu valoda (LV) (1.08 MB - PDF)

**First published:**

13/05/2024

**Last updated:**

03/09/2025

[View](/lv/documents/product-information/ryzneuta-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.05 MB - PDF)

**First published:**

13/05/2024

**Last updated:**

03/09/2025

[View](/lt/documents/product-information/ryzneuta-epar-product-information_lt.pdf)

magyar (HU) (1 MB - PDF)

**First published:**

13/05/2024

**Last updated:**

03/09/2025

[View](/hu/documents/product-information/ryzneuta-epar-product-information_hu.pdf)

Malti (MT) (1.09 MB - PDF)

**First published:**

13/05/2024

**Last updated:**

03/09/2025

[View](/mt/documents/product-information/ryzneuta-epar-product-information_mt.pdf)

Nederlands (NL) (1.02 MB - PDF)

**First published:**

13/05/2024

**Last updated:**

03/09/2025

[View](/nl/documents/product-information/ryzneuta-epar-product-information_nl.pdf)

norsk (NO) (1009.5 KB - PDF)

**First published:**

13/05/2024

**Last updated:**

03/09/2025

[View](/no/documents/product-information/ryzneuta-epar-product-information_no.pdf)

polski (PL) (1.06 MB - PDF)

**First published:**

13/05/2024

**Last updated:**

03/09/2025

[View](/pl/documents/product-information/ryzneuta-epar-product-information_pl.pdf)

português (PT) (1005.38 KB - PDF)

**First published:**

13/05/2024

**Last updated:**

03/09/2025

[View](/pt/documents/product-information/ryzneuta-epar-product-information_pt.pdf)

română (RO) (1.09 MB - PDF)

**First published:**

13/05/2024

**Last updated:**

03/09/2025

[View](/ro/documents/product-information/ryzneuta-epar-product-information_ro.pdf)

slovenčina (SK) (1.06 MB - PDF)

**First published:**

13/05/2024

**Last updated:**

03/09/2025

[View](/sk/documents/product-information/ryzneuta-epar-product-information_sk.pdf)

slovenščina (SL) (1.09 MB - PDF)

**First published:**

13/05/2024

**Last updated:**

03/09/2025

[View](/sl/documents/product-information/ryzneuta-epar-product-information_sl.pdf)

Suomi (FI) (1 MB - PDF)

**First published:**

13/05/2024

**Last updated:**

03/09/2025

[View](/fi/documents/product-information/ryzneuta-epar-product-information_fi.pdf)

svenska (SV) (1 MB - PDF)

**First published:**

13/05/2024

**Last updated:**

03/09/2025

[View](/sv/documents/product-information/ryzneuta-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000250203 19/06/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Ryzneuta : EPAR - All authorised presentations

English (EN) (38.41 KB - PDF)

**First published:** 13/05/2024

[View](/en/documents/all-authorised-presentations/ryzneuta-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-342)

български (BG) (48.02 KB - PDF)

**First published:**

13/05/2024

[View](/bg/documents/all-authorised-presentations/ryzneuta-epar-all-authorised-presentations_bg.pdf)

español (ES) (38.15 KB - PDF)

**First published:**

13/05/2024

[View](/es/documents/all-authorised-presentations/ryzneuta-epar-all-authorised-presentations_es.pdf)

čeština (CS) (46.82 KB - PDF)

**First published:**

13/05/2024

[View](/cs/documents/all-authorised-presentations/ryzneuta-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (39.49 KB - PDF)

**First published:**

13/05/2024

[View](/da/documents/all-authorised-presentations/ryzneuta-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (39.8 KB - PDF)

**First published:**

13/05/2024

[View](/de/documents/all-authorised-presentations/ryzneuta-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (36.25 KB - PDF)

**First published:**

13/05/2024

[View](/et/documents/all-authorised-presentations/ryzneuta-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (53.29 KB - PDF)

**First published:**

13/05/2024

[View](/el/documents/all-authorised-presentations/ryzneuta-epar-all-authorised-presentations_el.pdf)

français (FR) (37.87 KB - PDF)

**First published:**

13/05/2024

[View](/fr/documents/all-authorised-presentations/ryzneuta-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (46.9 KB - PDF)

**First published:**

13/05/2024

[View](/hr/documents/all-authorised-presentations/ryzneuta-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (38.31 KB - PDF)

**First published:**

13/05/2024

[View](/is/documents/all-authorised-presentations/ryzneuta-epar-all-authorised-presentations_is.pdf)

italiano (IT) (37.63 KB - PDF)

**First published:**

13/05/2024

[View](/it/documents/all-authorised-presentations/ryzneuta-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (55.73 KB - PDF)

**First published:**

13/05/2024

[View](/lv/documents/all-authorised-presentations/ryzneuta-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (55.72 KB - PDF)

**First published:**

13/05/2024

[View](/lt/documents/all-authorised-presentations/ryzneuta-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (58.32 KB - PDF)

**First published:**

13/05/2024

[View](/hu/documents/all-authorised-presentations/ryzneuta-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (58.32 KB - PDF)

**First published:**

13/05/2024

[View](/mt/documents/all-authorised-presentations/ryzneuta-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (38.28 KB - PDF)

**First published:**

13/05/2024

[View](/nl/documents/all-authorised-presentations/ryzneuta-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (39.5 KB - PDF)

**First published:**

13/05/2024

[View](/no/documents/all-authorised-presentations/ryzneuta-epar-all-authorised-presentations_no.pdf)

polski (PL) (57.67 KB - PDF)

**First published:**

13/05/2024

[View](/pl/documents/all-authorised-presentations/ryzneuta-epar-all-authorised-presentations_pl.pdf)

português (PT) (39.18 KB - PDF)

**First published:**

13/05/2024

[View](/pt/documents/all-authorised-presentations/ryzneuta-epar-all-authorised-presentations_pt.pdf)

română (RO) (45.77 KB - PDF)

**First published:**

13/05/2024

[View](/ro/documents/all-authorised-presentations/ryzneuta-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (55.61 KB - PDF)

**First published:**

13/05/2024

[View](/sk/documents/all-authorised-presentations/ryzneuta-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (44.99 KB - PDF)

**First published:**

13/05/2024

[View](/sl/documents/all-authorised-presentations/ryzneuta-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (36.42 KB - PDF)

**First published:**

13/05/2024

[View](/fi/documents/all-authorised-presentations/ryzneuta-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (38.35 KB - PDF)

**First published:**

13/05/2024

[View](/sv/documents/all-authorised-presentations/ryzneuta-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Ryzneuta Active substance efbemalenograstim alfa International non-proprietary name (INN) or common name efbemalenograstim alfa Anatomical therapeutic chemical (ATC) code L03AA18

### Pharmacotherapeutic group

Immunostimulants

### Therapeutic indication

Ryzneuta is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).

## Authorisation details

EMA product number EMEA/H/C/005828

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Marketing authorisation holder

Evive Biotechnology Ireland Limited

20 Kildare Street Dublin 2 D02 T3V7 Ireland

Opinion adopted 25/01/2023 Marketing authorisation issued 21/03/2024 Revision 3

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Ryzneuta : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (144.28 KB - PDF)

**First published:** 03/09/2025

[View](/en/documents/procedural-steps-after/ryzneuta-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Ryzneuta : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (148.23 KB - PDF)

**First published:** 15/05/2024

**Last updated:** 03/09/2025

[View](/en/documents/procedural-steps-after/ryzneuta-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Ryzneuta : EPAR - Public assessment report

Adopted

Reference Number: EMA/62813/2024

English (EN) (5.24 MB - PDF)

**First published:** 13/05/2024

[View](/en/documents/assessment-report/ryzneuta-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Ryzneuta

Reference Number: EMA/CHMP/31327/2024

English (EN) (117.15 KB - PDF)

**First published:** 26/01/2024

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-ryzneuta_en.pdf)

#### News on Ryzneuta

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 January 2024](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-january-2024) 26/01/2024

**This page was last updated on** 03/09/2025

## Share this page

[Back to top](#main-content)